Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Hepatology. 2012 Oct 14;56(5):1602–1610. doi: 10.1002/hep.25821

Fig. 7. Rituximab treatment normalizes mature B-cell subsets.

Fig. 7

Paired analysis of the frequency of naïve (A) and activated B-cells (B) within the CD19+ B-cell population prior to and 12 months after Rituximab treatment, compared to the corresponding B-cell percentages in uninfected controls. *p<0.05, ***p<0.001.